The DarwinOncoTarget™ and DarwinOncoTreat™ tests analyze whole transcriptome sequencing (RNASeq) of a patient-derived tumor sample to identify aberrantly activated proteins for which a clinically-relevant targeted inhibitor already exists and to match tumor-specific dependencies with clinically-relevant drugs, respectively. By clinically-relevant we mean FDA approved drugs as well as investigational drugs in Phase 2 and 3 clinical trials. More specifically, the DarwinOncoTarget™ test currently assesses aberrant activity of 193 proteins that can be targeted by 94 FDA approved oncology drugs, and by 239 investigational oncology agents. These numbers will change as more information becomes available. The DarwinOncoTreat™ test first identifies tumor-checkpoints comprising master regulator proteins that represent critical tumor dependencies; this is accomplished by assessing the concerted activity of 6,293 regulatory proteins. It then prioritizes drugs based on their experimentally tested ability to revert the activity of the tumor checkpoint in appropriate cell line models. While DarwinOncoTarget™ is available for all human malignancies, DarwinOncoTreat™ is currently available only for specific tumor subtypes for which the experimental assessment has already been completed (currently, breast carcinoma, glioblastoma multiforme, meningioma, neuroendocrine tumors, and sarcomas). Additional tumor subtypes will be added as the experimental validation data becomes available.
For patients with advanced cancers who have failed standard therapy these results may help the oncologist prioritize potential drug targets or select clinical trials.
|Methodology:||Cancer whole transcriptome analysis using regulatory network-based inference of protein activity (DarwinOncoTarget™ and Darwin Oncotreat™) of RNA obtained from FFPE or frozen tissue that contains at least 50% tumor.|
|Turnaround Time:||21 days|
|Samples Tested:||FFPE and frozen tissue.|
|Forms:||PGM OncoTarget Testing Requisition Form|
Precision Oncology: New Tests Look Beyond Genes
Two new precision medicine tests that look beyond cancer genes to identify novel therapeutic targets have just received New York State Department of Health approval and are now available to both oncologists and cancer researchers for use at the front lines of patient care.